Advertisement

  • News
  • Columns
  • Interviews
  • BW Communities
  • Events
  • BW TV
  • Subscribe to Print

Latest Articles in sun pharma

Sun Pharma's Halol Facility In USFDA's 'Import Alert List', US Entry Restricted For Products

The Import Alert implies interalia, that all future shipments of products manufactured at this facility are subject to refusal of admission to the US market until the facility becomes compliant with cGMP standards

Read More

Q2 Results: Sun Pharma Sales Up By 10% YoY, Records Net profit Of 2,262 Cr

The company’s sales in India saw a jump of 8.5 per cent to Rs 3,460 crore, a rise of 8.5 per cent against the second quarter of last year. At the same time, the sales in the US were up by 27.5 per cent quarter on quarter and stood at USD 200 million

Read More

Pharma Such As Glenmark, Sun Pharma, Dr Reddy's Recall Drugs In US

As per the USFDA, a Class III recall is initiated in a "situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences. "As per the USFDA, Sun Pharma is recalling 9,552 bottles of epilepsy treatment drug Divalproex Sodium delayed-release tablets due to "Failed Dissolution Specifications"

Read More

Sun Pharma, Glenmark Recalling Products From US Due To Manufacturing Woes

As per the latest enforcement report by the US Food and Drug Administration (USFDA), a US-based unit of Sun Pharma is recalling 50,680 vials of Testosterone Cypionate Injection, used to treat low testosterone in adult males, in the American market

Read More

Sun Pharma To Expand Field Force In India By 10% In FY23

Supported by more than 40 manufacturing facilities, Sun Pharma caters to more than 100 countries across the globe

Read More

Sun Pharma Eyes High Single Digit Top Line Growth In FY23: Dilip Shanghvi

On its Halol-based manufacturing plant, he stated that the company will be filing its response to the FDA on the corrective actions to be undertaken to address the observations within the stipulated time

Read More

Sun Pharma, Ranbaxy Inc Sign Pact With 2 Plaintiff Groups To Settle Claims

Sun Pharma said has disputed the claims of the plaintiffs and defended these matters vigorously

Read More

Sun Pharma To Set Up An End-To-End Manufacturing Facility In Andhra Pradesh

Sun Pharma is the fourth largest specialty generic pharmaceutical company in the world with global revenues of over US$ 4.5 billion. Supported by more than 40 manufacturing facilities, they provide high-quality, affordable medicines, trusted by healthcare professionals and patients, to more than 100 countries across the globe.

Read More

Sun Pharma, Lupin Recall Products In US Market, Says USFDA

New Jersey-based Sun Pharmaceutical Industries Inc, a unit of the company, has initiated the Class III nationwide (US) recall of the 10-count blister packs on October 12 this year.

Read More

Sun Pharma Q2 Net Profit Rises 13% To Rs 2,047 Cr

The company had posted a net profit of Rs 1,812.79 crore for the corresponding period of the previous fiscal, Sun Pharma said in a regulatory filing.

Read More

Sun Pharma, Cassiopea Spa Ink License & Supply Agreements For Acne Treatment Drug Winlevi

The USFDA approved Winlevi (clascoterone cream 1 per cent) in August 2020, for the topical treatment of acne vulgaris in patients 12 years and older.

Read More

Sun Pharma Settles Patent Litigation With Celgene Corporation For Cancer Drug Revlimid

Shares of Sun Pharma were trading 0.19 per cent lower at Rs 669.95 apiece on BSE.

Read More

Dilip Shanghvi Resigns As MD Of SPARC

Prior to joining SPARC, Raghavan served as the managing director of the India and Sri Lanka business of Quintiles, a global pharmaceutical services company.

Read More

Lupin, Sun Pharma, Jubilant Cadista Recall Drugs In US Market

The affected lot has been produced by Jubilant Generics at its Roorkee based plant in Uttarakhand and marketed in the US by Salisbury-based Jubilant Cadista Pharmaceuticals, Inc.

Read More

Markets Eke Out Slim Gains In Choppy Trade; RBI Policy Eyed

Domestic equities were quite volatile and gave up most initial gains as sharp spike in COVID-19 cases across the country and resultant mobility restrictions continued to weigh on investors’ sentiments

Read More